Abstract
Dupilumab has demonstrated efficacy in atopic dermatitis (AD)1–3, asthma4, perennial allergic rhinitis5 and chronic sinusitis6. The objectives of this prospective observational, single‐centre study were to assess 1) dupilumab efficacy in real‐life practice and 2) the evolution of atopic co‐morbidities and specific immunoglobulin E (IgE) levels during dupilumab treatment.
This article is protected by copyright. All rights reserved.
http://bit.ly/2H5knKP
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου